Challenges to Equal Access in MS Treatment

The Medicaid group exhibited higher rates of MS-related complications than did the commercial group, such as gait abnormalities (17.3% vs 10.4%); burning, numbness or tingling (21.9% vs 17.9%); dizziness/vertigo (14.6% vs 9.2%); and urinary incontinence (16.0% vs 5.8%; P < .001 for all). The Medicaid group also had a higher rate with nearly all comorbidities, such as hypertension (35.7% vs 30.2%), diabetes (16.6% vs 9.6%) and asthma (15.9% vs 6.0%; P < .001 for all). (19)